Lipocine (LPCN) Shares Outstanding (2011 - 2025)
Lipocine's (LPCN) quarterly Shares Outstanding (Entity) came in at $6.2 million in Q4 2025, up 15.16% YoY from $5.3 million in Q4 2024, and up 13.62% on a QoQ basis from $5.4 million in Q3 2025.
Lipocine (LPCN) Shares Outstanding (2011 - 2025) Analysis & Trends
Lipocine (LPCN) has 15 years of Shares Outstanding (Entity) data on file, last reported at $6.2 million in Q4 2025.
- Quarterly Shares Outstanding (Entity) rose 15.16% year-over-year to $6.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.2 million (up 15.16% YoY) and the FY2025 annual result came in at $6.2 million, up 15.16% from the prior year.
- Shares Outstanding (Entity) advanced to $6.2 million in Q4 2025, from $5.4 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $6.2 million in Q4 2025 to a low of $5.2 million in Q1 2021.
- A 5-year average of $5.3 million and a median of $5.3 million in 2023 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2021 — Shares Outstanding (Entity) surged 84.5% — and 2023, when it gained 0.01%.
- Tracing LPCN's Shares Outstanding (Entity) over 5 years: stood at $5.2 million in 2021, then climbed by 0.25% to $5.2 million in 2022, then gained by 2.11% to $5.3 million in 2023, then rose by 0.6% to $5.3 million in 2024, then increased by 15.16% to $6.2 million in 2025.
- The last three Shares Outstanding (Entity) figures came in at $6.2 million (Q4 2025), $5.4 million (Q3 2025), and $5.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | 5.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.41 Mn |
| Sep 30, 2025 | 5.41 Mn |
| Jun 30, 2025 | 5.35 Mn |
| Mar 31, 2025 | 5.35 Mn |
| Dec 31, 2024 | 5.34 Mn |
| Sep 30, 2024 | 5.35 Mn |
| Jun 30, 2024 | 5.34 Mn |
| Mar 31, 2024 | 5.32 Mn |
| Dec 31, 2023 | 5.27 Mn |
| Sep 30, 2023 | 5.29 Mn |
| Jun 30, 2023 | 5.23 Mn |
| Mar 31, 2023 | 5.21 Mn |
| Dec 31, 2022 | 5.20 Mn |
| Sep 30, 2022 | 5.21 Mn |
| Jun 30, 2022 | 5.21 Mn |
| Mar 31, 2022 | 5.19 Mn |
| Dec 31, 2021 | 5.11 Mn |
| Sep 30, 2021 | 5.19 Mn |
| Jun 30, 2021 | 5.19 Mn |
| Mar 31, 2021 | 4.82 Mn |